Luigi Petramala

Combined SGLT-2 Inhibitor and Mineralocorticoid Receptor Antagonist Therapy: Effects on the Renin–Angiotensin–Aldosterone System in Heart Failure Treatment

Sodium–glucose cotransporter 2 inhibitors (SGLT2is), originally developed as glucose-lowering agents for type 2 diabetes mellitus, have increasingly demonstrated clinical benefits in patients with chronic kidney disease and heart failure. We retrospectively evaluated 114 patients...